Back to today’s briefing

Story perspectives

U.S. to Invest in HIV Drug for 2 Million by 2028

9/5/2025

39 6

Summary

Story summary

The U.S. plans to invest in lenacapavir, an HIV prevention drug, targeting 2 million people by 2028.
Lenacapavir is considered a breakthrough, providing near-complete protection with biannual injections.
The initiative will prioritize preventing mother-to-child transmission and will collaborate with the Global Fund.
Approval for distribution from African countries is anticipated by early next year.

1 of 1

Story summary

The U.S. plans to invest in lenacapavir, an HIV prevention drug, targeting 2 million people by 2028.
Lenacapavir is considered a breakthrough, providing near-complete protection with biannual injections.
The initiative will prioritize preventing mother-to-child transmission and will collaborate with the Global Fund.
Approval for distribution from African countries is anticipated by early next year.